Navigation Links
Pharmasset Receives Notice of Allowance
Date:6/26/2008

ected.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Kurt Leutzinger

Chief Financial Officer

kurt.leutzinger@pharmasset.com

Office: +1 (609) 613-4110

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation the risk that the USPTO will withdraw the Notice of Allowance, adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that we cannot enroll enough patients for the Phase 3 registration clinical trial for clevudine, the risk that our collaboration with
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... -- Pharmavite LLC announced that Timothy "Tim" Toll has ... Toll recently served as Pharmavite,s executive vice president of ... label and sales administration in the United ... will expand his responsibilities to include international sales, global ... to chief customer officer is part of a plan ...
(Date:7/23/2014)... 23, 2014 /PRNewswire-iReach/ -- The Centers for Medicare & ... Innovation Network-Quality Improvement Organization (QIN-QIO) contract to a partnership ... Effective August 1, WVMI will launch Quality Insights ... , Pennsylvania , Delaware ... Louisiana.  The Network will engage providers and the community ...
(Date:7/23/2014)... /PRNewswire-iReach/ -- Use of Risk Evaluation and Mitigation Strategies ... market entry results in $5.4 billion in lost savings ... by economic consulting firm Matrix Global Advisors ... Required by the Food and Drug Administration ... are intended to improve drug safety by ensuring that ...
Breaking Medicine Technology:Announcing a New Regional Approach to Medicare Quality Improvement 2New Analysis Finds $5.4 Billion In Annual Lost Savings From Strategies Geared Toward Delaying Generic Drug Entry 2
... Texas, July 14, 2011 Convergen LifeSciences ... 7,977,468 has been awarded by the U.S. Patent and ... Board of Regents and The Secretary, U.S. Department of ... of 23 patents, pending or issued worldwide, licensed exclusively to ...
... REDWOOD CITY, Calif., July 14, 2011 Codexis, Inc. (Nasdaq: ... in the 13th Annual Pacific Crest Global Technology Leadership Forum, ... Robert Lawson, Senior Vice President and Chief Financial Officer, will ... Biofuels and Renewable Chemicals," scheduled for August 8 at 12:30 ...
Cached Medicine Technology:Convergen LifeSciences Announces Patent Award 2
(Date:7/23/2014)... Greenville, SC (PRWEB) July 23, 2014 AidJoy ... celebration of philanthropy at Zen on September 5, ... business community and AidJoy supporters are expected to attend this ... of our triumphs of the past six years," says Jess ... time to pause to reflect on this moment in AidJoy’s ...
(Date:7/23/2014)... "I wanted a better way to keep track of all ... pressure and pulse rate," said an inventor from Long Beach, ... a bunch of different devices, so I invented one that ... to make it easier to monitor health conditions. The invention ... enables the user to have more control over his or ...
(Date:7/23/2014)... athletes who suffered repeated blows to the head during ... Those clumps suggest the athletes had a disease called ... tests that might be able to detect CTE in ... Chemical & Engineering News (C&EN) , the weekly news ... article, Lauren Wolf, a senior editor at C&EN, explains ...
(Date:7/23/2014)... The Centers for Disease Control and Prevention applauded ... 2010 to 2012. Formerly known as “the nation’s medicine ... to some of the strongest opiates, such as Oxycontin, which ... launched an initiative to crack down on these rampant pill ... that existed in the state just a few years ago. ...
(Date:7/23/2014)... Fla. (PRWEB) July 23, 2014 ... results from leading academic institutions uncovering the importance ... opinions surrounding the need for breast self-exams is ... there is proof today for keeping this healthy ... cases mislead about the significance of breast self-exams ...
Breaking Medicine News(10 mins):Health News:AidJoy’s Inaugural Gala to be Held September 5, 2014 2Health News:Florida’s Crackdown on Pill Mills Has Led to Rise in Popularity of Synthetic Drugs; Suncoast Rehab Educates on Dangers of These Drugs in Adolescents 2Health News:Florida’s Crackdown on Pill Mills Has Led to Rise in Popularity of Synthetic Drugs; Suncoast Rehab Educates on Dangers of These Drugs in Adolescents 3Health News:Florida’s Crackdown on Pill Mills Has Led to Rise in Popularity of Synthetic Drugs; Suncoast Rehab Educates on Dangers of These Drugs in Adolescents 4Health News:Historical and Current Research Points to Importance of Breast Self-Exams 2
... for New York Blood Center (NYBC), NEW YORK, ... a blood drive on Monday, June 2 at 1011 ... School Gymnasium. Hours are from,9:30am-3:00pm, The Archdiocese of ... York,Blood Center; His Eminence Edward Cardinal Egan serves as ...
... WASHINGTON, May 30 The Department of,Veterans Affairs (VA) ... identified as being ill or injured from Operation,Enduring Freedom ... over 500,000 OEF-OIF veterans who have been,discharged from active ... "We promised to reach out to every OEF ...
... whole milk is just as effective, costs less and is ... is also commonly used as an oral contrast agent in conjunction ... , The study included 215 patients undergoing abdominal and pelvic CT, ... patients were given an IV contrast media; 115 were also given ...
... Results from a pivotal Phase III clinical ... once-daily, investigational anticoagulant medication, was superior in preventing ... knee replacement (TKR) surgery. The head-to-head study compared ... the current standard of care. , Data from ...
... May 30 Insulet Corporation,(Nasdaq: PODD ), ... its,OmniPod(R) Insulin Management System, today announced the company ... Obesity Conference.,Management is scheduled to present an overview ... June 6, 2008 at The Hotel Nikko in ...
... New Video ,Milestones in Oncology, Presentations at ... Society for Translational Oncology,(STO) is pleased to announce ... valuable video presentations for practicing,oncologists., (Logo: ... on the occasion of the 2008 Annual Meeting ...
Cached Medicine News:Health News:New York's Catholic Archdiocese Hosting June 2 Blood Drive 2Health News:VA Begins Next Phase of Combat Vet Outreach 2Health News:Rivaroxaban phase III pivotal data presented at EFORT annual meeting 2Health News:Rivaroxaban phase III pivotal data presented at EFORT annual meeting 3Health News:Society for Translational Oncology Launches Updated Website 2
... contact lens cleaning solution is ... and professionally proven cleaner. A ... resulting in a very effective ... cosmetic residue, salts, mucous and ...
Round knurled handle. Overall length 130 mm....
Alvis foreign body spud 4 3/4 inches, oval curette 1 x 3 mm with fine point....
Foreign body spud angled, lightly rounded tip....
Medicine Products: